Day One (DAWN) Soars 100% on $2.5-Billion Merger

Core Viewpoint - Day One Biopharmaceuticals Inc. is experiencing significant investor interest following its announcement of being acquired by Servier for $2.5 billion, resulting in a 100% increase in its stock price week-on-week, with a tender offer reflecting a 68% premium over its previous closing price [1][3]. Group 1: Acquisition Details - Day One Biopharmaceuticals will be acquired by France-based Servier, with all outstanding shares being tendered at $21.50 each, representing a 68% upside from the prior closing price of $12.78 [3]. - The transaction is expected to close in the second quarter of the year, pending customary closing conditions, including shareholder approval [3]. Group 2: Strategic Fit and Future Outlook - The CEO of Day One Biopharmaceuticals emphasized that Servier's successful track record in rare cancers and commitment to targeted therapies aligns with Day One's mission to provide medicines for patients with life-threatening diseases [4]. - The acquisition is seen as an opportunity to enhance the reach of Day One's scientific advancements, particularly in pediatric low-grade glioma, while maintaining a patient-first approach [5].